January 05, 2016

Q2 Solutions Comprehensive Cancer Panel

Targeted sequencing assay
The Q2 Solutions Comprehensive Cancer Panel is a targeted gene sequencing assay for analysis of genomic variation predictive of response to therapies in clinical development. Learn how you can take advantage of our Genomic Know-How® for your drug development needs, including a range of genomic services to support oncology clinical development by identifying markers for drug efficacy, toxicity and responsiveness in a comprehensive and personalized fashion. Our genomic services fully integrate into our central laboratory and clinical trial solutions throughout the drug development lifecycle. Download to learn more and to see the full cancer panel content.

Related Services:
Systematic Design and Development of the Q2 Solutions Comprehensive Cancer Panel

A Case Study in Iterative Design and Validation

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Read More